Everads Presents Clinical Data from First-in-Human Trial of Suprachoroidal Delivery Technology at EURETINA
1st cohort data demonstrates safety, feasibility and tolerability of the Everads Injector for delivering drugs to the back of the eye via thesuprachoroidal space Results validate use of the Injector in a clinical, office-based setting, and will supportthe clinical trial applications of Everads’ gene therapy license partners Everads Therapy,a clinical stage biotechnology company developing a […]